Trial Profile

A phase II randomized, placebo-controlled, observer-blind, multicenter clinical trial of a recombinant plague vaccine adjuvanted with CpG 1018

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Nov 2024 According to a Dynavax Technologies media release, Based on the results from this trial, company has has submitted a proposal to the U.S. Department of Defense (DoD) regarding additional clinical and manufacturing activities.
02 Nov 2023 According to a Dynavax Technologies media release, dosing has been completed in this study.
02 May 2023 According Dynavax Technologies media release, Part 1 successfully completed in January 2023 and the company recently completed enrollment in Part 2 of the Phase 2 clinical trial, with top line data anticipated in 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com